• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

    7/7/25 11:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email

    Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer

    PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administration (FDA), and assignment by the Centers for Medicare and Medicaid Services (CMS) of a benefit category and unique Health Care Common Procedure Coding System (HCPCPS) code, will transition to the role of Chief Scientific Officer (CSO) and work with Larry to build the market and grow the company in its next phase.

    (PRNewsfoto/MedRhythms)

    Mr. Jasinski brings more than three decades of executive leadership in the medical device and neurotechnology industries. Most recently, he served as CEO of Lifeward (NASDAQ:LFWD), formerly ReWalk Robotics, where he led the company through a successful IPO and secured national reimbursement for the first exoskeleton system for spinal cord injury. Prior to that, he was President and CEO of Soteira, Inc., which was acquired by Globus Medical in 2012.

    "After a rigorous, international search process, the Board of Directors Search Committee unanimously and enthusiastically selected Larry as MedRhythms' next CEO. The Board and major investors are excited to welcome Larry to MedRhythms and eagerly look forward to his leadership of our great team into the next phase of company growth," said Jean Hoffman, Board Member and Chair of the CEO Search Committee.

    "MedRhythms has innovative fundamental technology, well-established published clinical data on effectiveness, an elegant and easy-to-use product with good margins, will operate in sizable market segments and has gained CMS and other coverage," said Larry Jasinski. "MedRhythms will improve many lives and is positioned to become a valuable business entity. I'm honored to join this mission-driven team and look forward to accelerating our growth and impact on patients' lives."

    Co-founder Brian Harris added, "MedRhythms was founded on the vision and mission of transforming patients' lives and Larry has dedicated his career to that same mission. His experience is an ideal fit for the next important phase of the company, and I look forward to working with him to continue to advance the company's mission and increase its impact in bringing important care to patients who need and deserve it."

    Jasinski's appointment marks a critical inflection point for MedRhythms, as the company prepares for national expansion of its home-use products for walking impairments: InTandem®, for chronic stroke, and Movive™, for Parkinson's disease. Both products are FDA-listed, Class II devices and are now available for federal healthcare distribution. As CEO, Jasinski will lead MedRhythms' strategic expansion, accelerate market adoption and build on its robust clinical foundation to bring the company's groundbreaking platform to more patients with chronic health and mobility conditions.

    About MedRhythms

    MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. The company is developing a pipeline of products across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease.  In 2021, the company partnered with Universal Music Group and raised a Series B financing round led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine.

    For more information, visit www.medrhythms.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medrhythms-appoints-larry-jasinski-as-chief-executive-officer-to-lead-next-phase-of-growth-and-commercial-expansion-302498926.html

    SOURCE MedRhythms

    Get the next $LFWD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rose Keith Dale was granted 15,000 units of Ordinary Shares, increasing direct ownership by 720% to 17,083 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    5/20/26 8:15:43 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    New insider Rose Keith Dale claimed ownership of 2,083 units of Ordinary Shares (SEC Form 3)

    3 - Lifeward Ltd. (0001607962) (Issuer)

    5/20/26 8:13:57 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    New insider Oramed Pharmaceuticals Inc. claimed ownership of 1,250,363 units of Ordinary Shares (SEC Form 3)

    3 - Lifeward Ltd. (0001607962) (Issuer)

    5/14/26 5:19:35 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

    Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of

    5/19/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Reports First Quarter 2026 Financial Results

    Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNE

    5/15/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll fre

    5/11/26 9:25:58 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    SEC Filings

    View All

    SEC Form SD filed by Lifeward Ltd.

    SD - Lifeward Ltd. (0001607962) (Filer)

    5/29/26 4:05:19 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Lifeward Ltd.

    S-8 - Lifeward Ltd. (0001607962) (Filer)

    5/20/26 5:01:03 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Lifeward Ltd.

    10-Q - Lifeward Ltd. (0001607962) (Filer)

    5/20/26 4:24:54 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/17/24 8:55:09 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/27/24 8:03:53 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/26/24 7:07:36 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Lifeward with a new price target

    Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

    2/10/25 7:00:44 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Financials

    Live finance-specific insights

    View All

    Lifeward Reports First Quarter 2026 Financial Results

    Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNE

    5/15/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll fre

    5/11/26 9:25:58 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

    Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co

    3/13/26 8:00:00 AM ET
    $LFWD
    $ORMP
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LFWD
    Leadership Updates

    Live Leadership Updates

    View All

    Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

    Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of

    5/19/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Appoints Bob Marshall as Chairman of the Board

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. "On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader

    12/19/25 4:05:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

    Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati

    7/7/25 11:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care